期刊文献+

温胆汤加减联合利培酮治疗首发精神分裂症的临床疗效分析 被引量:10

温胆汤加减联合利培酮治疗首发精神分裂症的临床疗效分析
下载PDF
导出
摘要 目的探讨温胆汤加减联合利培酮治疗首发精神分裂症的临床效果。方法 104例首发精神分裂症患者随机分为治疗组和对照组,全部病例给予利培酮治疗,治疗组另外给予温胆汤加减治疗,疗程60d。评价两组临床疗效和中医证候疗效,比较两组BPRS、PANSS量表评分,观察不良反应。结果治疗组临床疗效总有效率为88.9%,显著高于对照组(50.0%)(P<0.05);治疗组中医证候疗效总有效率为87.0%,显著高于对照组(48.0%)(P<0.05);治疗组BPRS和PANSS量表评分显著低于对照组(P<0.05);治疗组不良反应发生率显著低于对照组(P<0.05)。结论温胆汤加减联合利培酮治疗首发精神分裂症是一种安全、有效的治疗方法 ,临床值得推广应用。 Objective To investigate the clinical effect of of wendan decoction combined with risperidone for treatment of first-case schizophrenia. Methods 104 patients with first-case schizophrenia were randomly divided into treatment group and control group,all cases were given risperidone treatment, while the treatment group was given treatment of wendan decoction,treatment for 60 days.The clinical effect and TCM clinical efficacy were evaluated, the BPRS and PANSS scores were compared and the adverse reactions were observed.Results The total effective rate of clinical efficacy was 88.9%,it was significantly higher than that of the control group(50.0%)(P0.05);the total effective rate of TCM clinical efficacy was 87.0%,it was significantly higher than that of the control group(48.0%)(P0.05);the adverse reactions of the treatment group was significantly lower than that of the control group(P0.05). Conclusion The wendan decoction combined with risperidone for treatment of first-case schizophrenia is safe and effective,it is worth clinical application.
作者 林升
出处 《当代医学》 2010年第20期156-157,共2页 Contemporary Medicine
关键词 首发精神分裂症 温胆汤加减 利培酮 First-case schizophrenia Wendan decoction Risperidone
  • 引文网络
  • 相关文献

参考文献9

二级参考文献73

共引文献93

同被引文献103

引证文献10

二级引证文献77

;
使用帮助 返回顶部